The extent of interactions with various biomolecules is a crucial feature of newly developed metallodrugs, worthy of thorough investigation, as its understanding helps uncover the fate of these xenobiotics in the physiological environment. In this work, promisingly cytotoxic half-sandwich complexes [Ru(η6-pcym)Cl(L1)]PF6 (1), [Ir(η5-Cp*)Cl(L1)]PF6 (2) and [Ir(η5-Cp*)Cl(L2)]PF6 (3), with 2-{n-[(E)-phenyldiazenyl]pyridin-2-yl}-1H-benzimidazole as a bidentate N-donor azo ligand (n = 5 for L1 and 6 for L2; pcym = p-cymene, Cp* = pentamethylcyclopentadienyl), were subjected to an extensive and detailed study of interactions with a plethora of extra- and intracellular biologically relevant molecules. For the first time in the field of anticancer half-sandwich complexes, mixtures of 3 with ascorbic acid (ASA) and its combinations with reduced glutathione (GSH) and/or reduced nicotinamide adenine dinucleotide (NADH) were studied. Complex 3 undergoes azo bond reduction when mixed with NADH or ASA, which oxidizes to NAD+ or dehydroascorbate (DHA), respectively. Intriguingly, the presence of the natural antioxidant ASA has a relevant prooxidative impact on GSH, which is connected with ASA recovery from DHA. Although the azo bond of L2 involved in 3 seems to be the reaction centre for the dehydrogenation reactions of the biomolecules, L2 by itself is a negligible oxidant and thus complexation in 3 represents a necessary prerequisite for the redox reactions.
Cancer cell selective antiproliferative activity of thiadiazole-based half-sandwich complexes in sensitive and resistant ovarian cancer cell lines is triggered by exchanging Ru for Ir and by switching the halido coligand from chloride to iodide.
Halogenido and carboxylato Ru(II) half-sandwich complexes of the general composition [Ru(η6-p-cym)(dpa)X]PF6 (1–5) were prepared and thoroughly characterized with various techniques (e.g., mass spectrometry, NMR spectroscopy and X-ray analysis); dpa = 2,2′-dipyridylamine; p-cym = p-cymene; X = Cl− (for 1), Br− (for 2), I− (for 3), valproate(1−) (for 4) or 4-phenylbutyrate(1−) (for 5). A single-crystal X-ray analysis showed a pseudo-octahedral piano-stool geometry of [Ru(η6-p-cym)(dpa)I]PF6 (3), with a η6-coordinated p-cymene, bidentate N-donor dpa ligand and iodido ligand coordinated to the Ru(II) atom. The results of the 1H-NMR solution behaviour studies proved that the complexes 1–5 hydrolyse were in the mixture of solvents used (10% MeOD-d4/90% D2O). Complexes 1–5 were in vitro inactive against the A2780 human ovarian carcinoma cell line, up to the highest tested concentration (IC50 > 100 μM).
Platinum-based agents unwaveringly hold their prominent position in cancer treatment. Current research emphasizes finding novel complexes for hard-to-treat cancers with minimum side effects, capable of overcoming resistance. This work presents easy-to-prepare diiodidoplatinum(II) complexes cis-[PtI2(Ln)2] (1–7) with imidazole derivatives (Ln), which were considerably effective against multiple myeloma cell lines U266B1 and KMS12-PE. The leading compound 6 (at 3 μM concentration) extraordinarily reduced viability of U266B1 and KMS12-PE myeloma cells to 3.0% and 1.1%, respectively, and exceeded the conventional platinum-based anticancer drug cisplatin (93.1% and 88.3%, respectively) that is used clinically for the combination therapy of multiple myeloma. Complex 6 was significantly more effective in inducing apoptosis in KMS12-PE cells without interleukin-6 (IL-6) expression than in U266B1 cells with IL-6 expression. Complex 6 also induced apoptosis in co-culture of KMS12-PE with non-cancerous stromal fibroblasts (HS-5), and displayed markedly lower activity in the HS-5 stromal fibroblast cells than in myeloma cells, pointing out its pharmocologically prospective selectivity towards the cancer cells over the normal ones. No caspase 3/7 activity was detected in apoptotic KMS12-PE cells treated by complex 6 indicating a different mechanism of apoptosis action from cisplatin. This work demonstrates that simple non-classical platinum(II) complexes represent a new perspective for a monotherapy of hard-to-treat multiple myeloma.